Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teneligliptin add-on to canagliflozin in Japanese type 2 diabetes
NCT02354222Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Jan 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Teneligliptin + Canagliflozin with Placebo + Canagliflozin (2 arms). Primary endpoint: Glycated Hemoglobin at 24 weeks. Started Jan 2015; status: completed.
02
Drugs
teneligliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02354222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354222.